Literature DB >> 26225065

Bisphosphonate-Related Osteonecrosis of the Jaws and Its Array of Manifestations.

Gustavo Davi Rabelo1, José Narciso Rosa Assunção2, Pascale Chavassieux3, Haroldo Arid Soares4, Fabio Abreu Alves5, Celso Augusto Lemos6.   

Abstract

PURPOSE: Bisphosphonate (BP) therapy in the treatment of bone diseases and malignancy may induce a major side effect known as bisphosphonate-related osteonecrosis of the jaws (BRONJ). A particular view of this condition is reported in this case series investigating eight patients. The aim of the study was to evaluate the BRONJ lesions concerning their aspects and progression. Also, identify if it is possible to predict the degree of severity in these cases.
METHODS: Patients were evaluated by their condition and systemic health. The lesions were evaluated in clinical and radiographic aspects. The patients were followed-up for 2 years.
RESULTS: The patients presented with specific peculiarities, and the BRONJ lesions varied in several characteristics. The BRONJ lesions ranged from simple to severe conditions, and the complicated cases presented with major pain, swelling, secondary infection and an extensive necrotic area, classified with high grade of severity.
CONCLUSIONS: The patients presented here confirm the existence of a relation between multiple features and BRONJ and to understand the whole process of aggravation, all systemic and local information have to be taken into account, together with all data related to the BP utilized. Regardless of the low incidence of this side effect in relation to osteoporosis treatment, in some cases, the BRONJ may become a severe condition and compromise the patient's quality of life.

Entities:  

Keywords:  Bisphosphonate; Cancer; Jaws; Osteonecrosis; Osteoporosis

Year:  2014        PMID: 26225065      PMCID: PMC4511882          DOI: 10.1007/s12663-014-0707-8

Source DB:  PubMed          Journal:  J Maxillofac Oral Surg        ISSN: 0972-8270


  15 in total

Review 1.  Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review.

Authors:  Cesar A Migliorati; Joel B Epstein; Elliot Abt; James R Berenson
Journal:  Nat Rev Endocrinol       Date:  2010-11-16       Impact factor: 43.330

Review 2.  Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment.

Authors:  Cesar A Migliorati; Michael A Siegel; Linda S Elting
Journal:  Lancet Oncol       Date:  2006-06       Impact factor: 41.316

3.  Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.

Authors:  P M Chavassieux; M E Arlot; C Reda; L Wei; A J Yates; P J Meunier
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

Review 4.  New understanding and treatments for osteoporosis.

Authors:  G Mazziotti; J Bilezikian; E Canalis; D Cocchi; A Giustina
Journal:  Endocrine       Date:  2012-02       Impact factor: 3.633

5.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

Review 6.  Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis.

Authors:  J Sarin; S S DeRossi; S O Akintoye
Journal:  Oral Dis       Date:  2008-04       Impact factor: 3.511

7.  Ninety-one osteoporosis patients affected with bisphosphonate-related osteonecrosis of the jaw: a case series.

Authors:  E Mercer; T Norton; S Woo; N Treister; T B Dodson; D H Solomon
Journal:  Calcif Tissue Int       Date:  2013-06-12       Impact factor: 4.333

8.  Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug.

Authors:  Robin J Young; Robert E Coleman
Journal:  Future Oncol       Date:  2013-05       Impact factor: 3.404

9.  Site specific effects of zoledronic acid during tibial and mandibular fracture repair.

Authors:  Yan Yiu Yu; Shirley Lieu; Diane Hu; Theodore Miclau; Céline Colnot
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

10.  Evaluation of socket healing in patients undergoing bisphosphonate therapy: experience of a single Institution.

Authors:  Gabriel-Fukunaga Kato; Rodrigo-Nascimento Lopes; Graziella-Chagas Jaguar; Ana-Paula Silva; Fabio-Abreu Alves
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2013-07-01
View more
  4 in total

Review 1.  Prevalence of dental alterations in patients under bisphosphonates therapy: a systematic review.

Authors:  Monique Abreu Pauli; Natália Cristina Trentin Bordignon; Geórgia Ribeiro Martini; Mariana Comparotto Minamisako; Rogério Gondak
Journal:  Oral Maxillofac Surg       Date:  2022-06-04

Review 2.  Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

Authors:  Athanasios D Anastasilakis; Jessica Pepe; Nicola Napoli; Andrea Palermo; Christos Magopoulos; Aliya A Khan; M Carola Zillikens; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

3.  Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study.

Authors:  Hironobu Hata; Kenji Imamachi; Michihiro Ueda; Masashi Matsuzaka; Hiroaki Hiraga; Toshihisa Osanai; Toru Harabayashi; Katsuya Fujimoto; Satoshi Oizumi; Masato Takahashi; Kazuhito Yoshikawa; Jun Sato; Yutaka Yamazaki; Yoshimasa Kitagawa
Journal:  Support Care Cancer       Date:  2022-02-03       Impact factor: 3.359

Review 4.  Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw.

Authors:  Lina He; Xiangyu Sun; Zhijie Liu; Yanfen Qiu; Yumei Niu
Journal:  Int J Oral Sci       Date:  2020-10-21       Impact factor: 6.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.